Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Regeneron Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Reports First Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ALNY REGN
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers REGN SNY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.